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Abstract
People with type 1 diabetes (T1D) lack the ability to produce the insulin their bodies need.
As a result, they must continually make decisions about how much insulin to self-administer
to adequately control their blood glucose levels. Longitudinal data streams captured from
wearables, like continuous glucose monitors, can help these individuals manage their health,
but currently the majority of the decision burden remains on the user. To relieve this
burden, researchers are working on closed-loop solutions that combine a continuous glucose
monitor and an insulin pump with a control algorithm in an ‘artificial pancreas.’ Such
systems aim to estimate and deliver the appropriate amount of insulin. Here, we develop
reinforcement learning (RL) techniques for automated blood glucose control. Through a
series of experiments, we compare the performance of different deep RL approaches to
non-RL approaches. We highlight the flexibility of RL approaches, demonstrating how
they can adapt to new individuals with little additional data. On over 2.1 million hours of
data from 30 simulated patients, our RL approach outperforms baseline control algorithms:
leading to a decrease in median glycemic risk of nearly 50% from 8.34 to 4.24 and a decrease
in total time hypoglycemic of 99.8%, from 4,610 days to 6. Moreover, these approaches are
able to adapt to predictable meal times (decreasing average risk by an additional 24% as
meals increase in predictability). This work demonstrates the potential of deep RL to help
people with T1D manage their blood glucose levels without requiring expert knowledge.
All of our code is publicly available, allowing for replication and extension.1
1. https://gitlab.eecs.umich.edu/mld3/rl4bg
c© 2020 I. Fox, J. Lee, R. Pop-Busui & J. Wiens.
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Deep RL for Blood Glucose Control
1. Introduction
Type 1 diabetes (T1D) is a chronic disease affecting 20-40 million people worldwide (You
and Henneberg, 2016), and its incidence is increasing (Tuomilehto, 2013). People with T1D
cannot produce insulin, a hormone that controls blood glucose levels, and must monitor
their blood glucose levels and manually administer insulin doses as needed. Administering
too little insulin can lead to hyperglycemia (high blood glucose levels), which results in
chronic health complications (Diabetes Control and Complications Trial Research Group,
1995), while administering too much insulin results in hypoglycemia (low blood glucose
levels), leading to coma or death. Getting the correct dose requires careful measurement of
glucose levels and carbohydrate intake, resulting in at least 15-17 data points a day. When
using a continuous glucose monitor (CGM), this can increase to over 300 data points, or a
blood glucose reading every 5 minutes (Coffen and Dahlquist, 2009).
CGMs with an insulin pump, a device that delivers insulin, can be used with a closed-loop
controller as an ‘artificial pancreas’ (AP). Though the technology behind CGMs and insulin
pumps has advanced, there remains significant room for improvement when it comes to the
control algorithms (Bothe et al., 2013; Pinsker et al., 2016). Current hybrid closed-loop
approaches require accurate meal announcements to maintain glucose control.
In this work, we investigate deep reinforcement learning (RL) for blood glucose control.
RL is a promising solution, as it is well-suited to learning complex behavior and readily
adapts to changing domains (Clavera et al., 2018). We hypothesize that deep RL, the
combination of RL with a deep neural network, will be able to accurately infer latent meals
to control insulin. Furthermore, as RL is a learning-based approach, we hypothesize that
RL will adapt to predictable meal schedules better than baseline approaches.
The fact that RL is learning-based means it requires data to work effectively. Unlike
many other health settings, there are credible simulators for blood glucose management
(Visentin et al., 2014). Having a simulator alleviates many concerns of applying RL to health
problems (Gottesman et al., 2018, 2019). However, that does not mean RL for blood glucose
control is straightforward, and, in this paper, we identify and address several challenges. To
the best of our knowledge, we present the first deep RL approach that achieves human-level
performance in controlling blood glucose without requiring meal announcements.
Generalizable Insights about Machine Learning in the Context of Healthcare
Applying deep RL to blood glucose management, we encountered challenges broadly relevant
for RL in healthcare. As such, we believe our solutions and insights, outlined below, are
broadly relevant as well.
• The range of insulin and carbohydrate requirements across patients makes it difficult
to find a single action space that balances the needs of rapid insulin administration
and safety. Indeed, many health problems involve changes in action distributions
across patients (e.g. in anesthesia dosing (Bouillon and Shafer, 1998)). To solve this
problem, we present a robust patient-specific action space that naturally encourages
safer policies.
• We found several pitfalls in evaluating our proposed approach that led to unrealistic
performance estimates. To address this issue, we used validation data to perform
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careful model selection, and used extensive test data to evaluate the quality of our
models. In RL, it is typical to report performance on the final trained model (without
model selection) over a handful of rollouts. Our experiments demonstrate the danger
of this approach.
• Deep RL has been shown to be unstable (Irpan, 2018; Henderson et al., 2018), often
achieving poor worst-case performance. This is unacceptable for safety-critical tasks,
such as those in healthcare. We found that a combination of simple and widely appli-
cable approaches stabilized performance. In particular, we used a safety-augmented
reward function, realistic randomness in training data, and random restarts to train
models that behaved safely over thousands of days of evaluation.
• Finally, unlike game settings where one has ability to learn from hundreds of thousands
of hours of interaction, any patient-specific model must be able to achieve strong
performance using a limited amount of data. We show that a simple transfer learning
approach can be remarkably sample efficient and can even surpass the performance of
models trained from scratch.
2. Background and Related Work
This work develops and applies techniques in reinforcement learning to the problem of blood
glucose management. To frame this work, we first provide a brief introduction to RL, both
in general and specifically applied to problems in healthcare. We then discuss how RL and
other approaches have been used for blood glucose control and present an overview on blood
glucose simulation.
2.1. Reinforcement Learning
RL is an approach to optimize sequential decision making in an environment, which is
typically assumed to follow a Markov Decision Process (MDP). An MDP is characterized by
a 5-tuple (S,A, P,R, γ), where s ∈ S are the states of the environment, a ∈ A are actions
that can be taken in the environment, the transition function P : (s, a) → s′ defines the
dynamics of the environment, the reward function R : (s, a)→ r ∈ R defines the desirability
of state-action pairs, and the discount factor γ ∈ [0, 1] determines the tradeoff between the
value of immediate and delayed rewards. The goal in RL is to learn a policy pi : s→ a, or
function mapping states to actions, that maximizes the expected cumulative reward, or:
arg max
pi∈Π
∞∑
t=1
Est∼P (st−1,at−1)[γ
tR(st, pi(st))], (1)
where Π is the space of possible policies and s0 ∈ S is the starting state. The state value
function, V (s), is the expected cumulative reward where s0 = s. The state-action value
function Q(s, a) = R(s, a) + Es′∼P (s,a)[γV (s′)] extends the notion of value to state-action
pairs.
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2.2. Reinforcement Learning in Healthcare
In recent years, researchers have started to explore RL in healthcare. Examples include
matching patients to treatment in the management of sepsis (Weng et al., 2017; Komorowski
et al., 2018) and mechanical ventilation (Prasad et al., 2017). In addition, RL has been
explored to provide contextual suggestions for behavioral modifications (Klasnja et al., 2019).
Despite its successes, RL has yet to be fully explored as a solution for a closed-loop AP
system (Bothe et al., 2013).
2.3. Algorithms for Blood Glucose Control
Among recent commercial AP products, proportional-integral-derivative (PID) control is the
most common backbone (Trevitt et al., 2015). The simplicity of PID controllers make them
easy to use, and in practice they achieve strong results (Steil, 2013). The Medtronic Hybrid
Closed-Loop system, one of the few commercially available, is built on a PID controller
(Garg et al., 2017; Ruiz et al., 2012). A hybrid closed-loop controller adjusts baseline insulin
rates but requires human intervention to control for the effect of meals. The main weakness
of PID controllers is their reactivity. As a result, they often cannot react fast enough to
meals, and thus rely on meal announcements (Garg et al., 2017). Additionally, without
safety modifications, PID controllers can deliver too much insulin, triggering hypoglycemia
(Ruiz et al., 2012). In contrast, we hypothesize that an RL approach will be able to leverage
patterns associated with meal times, resulting in more responsive and safer policies.
Previous works have examined RL for different aspects of blood glucose control. See
Tejedor et al. (2020) for a recent survey. Many of these works investigated the use of RL to
adapt existing insulin treatment regimens to learn a human-in-the-loop policy (Ngo et al.,
2018; Oroojeni Mohammad Javad et al., 2015; Sun et al., 2018). This contrasts with our
setting, where we aim to learn a fully closed-loop policy.
Like our work, Daskalaki et al. (2010) and De Paula et al. (2015) focus on the task
of closed-loop glucose control. Daskalaki et al. (2010) use direct future prediction to aid
PID-style control, substituting the problem of RL with prediction. De Paula et al. (2015)
use a policy-iteration framework with Gaussian process approximation and Bayesian active
learning. While they tackle a similar problem, these works use a simple simulator and a
fully deterministic meal routine for training and testing. In our experiments, we use an
FDA-approved glucose simulator and a realistic non-deterministic meal schedule, significantly
increasing the challenge.
2.4. Glucose Models and Simulation
Models of the glucoregulatory system are important for the development and testing of an AP
(Cobelli et al., 1982). In our experiments, we use the UVA/Padova model (Kovatchev et al.,
2009). This simulator models the glucoregulatory system as a nonlinear multi-compartment
system, where glucose is generated in the liver, absorbed through the gut, and controlled by
external insulin. A more detailed explanation can be found in Kovatchev et al. (2009). For
reproducibility, we use an open-source version of the simulator that comes with 30 virtual
patients (Xie, 2018). The parameter distribution of the patient population is determined by
age, and the simulator comes with 10 children, adolescents, and adults each Kovatchev et al.
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(2009). We combine the simulator with a non-deterministic meal schedule (Appendix A.1)
to realistically simulate patient behavior.
3. Methods
We present a deep RL approach well suited for blood glucose control. In framing our
problem, we pay special attention to the concerns of partial observability and safety. The
issue of partial observability motivates us to use a maximum entropy control algorithm,
soft actor-critic, combined with a recurrent neural network. Safety concerns inspire many
aspects of our experimental setup, including our choice of action space, reward function, and
evaluation metrics. We also introduce several strong baselines, both with and without meal
announcements, to which we compare.
3.1. Problem Setup
We frame the problem of closed-loop blood glucose control as a partially-observable Markov
decision process (POMDP) consisting of the 7-tuple (S∗, O, S,A, P,R, γ). A POMDP
generalizes the MDP setting described in Section 2.1 by assuming we do not have access
to the true environment states, here denoted s∗ ∈ S∗, but instead observe noisy states s ∈ S
according to the (potentially stochastic) observation function: O : s∗ → s. This setting
applies given the noise inherent in CGM sensors (Vettoretti et al., 2019) and our assumption
of unobserved meals.
In our setting, the true states s∗t ∈ S∗ are the 13-dimensional simulator states, as
described in Kovatchev et al. (2009). The stochastic observation function O : s∗t → bt, it
maps from the simulator state to the CGM observation bt and insulin it administered.
To provide temporal context, we augment our observed state space st ∈ S to include the
previous 4 hours of CGM bt and insulin data it at 5-minute resolution: st = [b
t, it] where:
bt = [bt−47, bt−46, . . . , bt], it = [it−47, it−46, . . . , it],
bt ∈ N40:400, it ∈ R+, and t ∈ N1:288 represents a time index for a day at 5-minute resolution.
Note that in our augmented formulation, the observation function no longer directly maps
to observed states, as observed states incorporate significant amounts of historical data. We
chose a 4-hour window, as we empirically found it led strong performance. We use a time
resolution of 5 minutes to mimic the sampling frequency of many common CGMs. Actions
at ∈ R≥0 are real positive numbers, denoting the size of the insulin bolus in medication
units.
The transition function P , our simulator, consists of two elements: i) M : t→ ct is the
meal schedule, and is defined in Appendix A.1, and ii) G : (at, ct, s
∗
t )→ (bt+1, it+1, s∗t+1),
where ct ∈ R≥0 is the amount of carbohydrates input at time t and G is the UVA/Padova
simulator (Kovatchev et al., 2009). Note that our meal schedule is patient-specific, and
includes randomness in the daily number, size, and timing of meals.
The reward function R : (st, at)→ R is defined as negative −risk(bt) where risk is the
Magni risk function:
risk(b) = 10 ∗ (c0 ∗ log(b)c1 − c2)2, (2)
5
Deep RL for Blood Glucose Control
Figure 1: The risk function proposed in (Magni et al., 2007). The mapping between blood
glucose values (in mg/dL, x-axis) and risk values (y-axis). Blood glucose levels corresponding
to hypoglycemia are shown in the blue shaded region, the glucose range corresponding to
hyperglycemia is shown in the red shaded region. This function identifies low blood glucose
values as higher risk than high blood glucose values, which is sensible given the rapidity of
hypoglycemia.
c0 = 3.35506, c1 = 0.8353, and c2 = 3.7932 (Magni et al., 2007). These values are set
such that risk(70) = risk(280) = 25, see Figure 1. Finally, we set γ = 0.99 for our
experiments, a value we determined empirically on validation data in combination with the
early termination penalty.
Considered in isolation, our reward could lead to dangerous behavior. As it is always
negative, cumulative reward is maximized by ending the episode as quickly as possible,
which occurs when glucose reaches unsafe levels. To avoid this, we add a termination penalty
of −1e5 to trajectories that enter dangerous blood glucose regimes (blood glucose levels
less than 10 or more than 1,000 mg/dL), countering the advantage of early termination.
We investigated other reward functions, such as time in range or distance from a target
blood glucose value, but found this reward worked best. It led to control schemes with
less hypoglycemia, as low blood glucose is penalized more heavily than high glucose. Low
glucose can occur quickly when large amounts of insulin are given without an accompanying
meal. Given the lack of meal announcements and sensor noise in our setting, avoiding
hypoglycemia was a significant challenge.
3.2. Soft Actor-Critic
We chose to use the soft actor-critic (SAC) algorithm to learn glucose control policies. We
initially experimented with a Deep-Q Network approach (Mnih et al., 2015). However,
choosing a discretized action space (as is required by Q-learning) that accounted for the
range of insulin values across a day and allowed exploration proved impractical, as large doses
of inappropriately timed insulin can be dangerous. Among continuous control algorithms,
we selected SAC as it has been shown to be sample efficient and competitive (Haarnoja
et al., 2018a). Additionally, maximum entropy policies like the ones produced by SAC can
do well in partially observed settings like our own (Eysenbach and Levine, 2019).
SAC produces a stochastic policy pi : st → p(a) ∀a ∈ A, which maps a state to a
distribution over possible actions. Under SAC, the policy (or actor) is represented by
6
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a neural network with parameters φ. Our network generates outputs µ, log(σ) which
parameterize a normal distribution N (µ, σ). The actions are distributed according to a
TanhNormal distribution, or tanh(z), z ∼ N (µ, σ). piφ is trained to maximize the maximum
entropy RL objective function:
J(pi) =
T∑
t=0
E(st,at)∼P (st−1,piφ(st−1))[R(st, at) + αH(piφ(·|st))], (3)
where entropy, H, is added to the expected cumulative reward to improve exploration
and robustness (Haarnoja et al., 2018a). Intuitively, the return in Equation 3 encourages a
policy that can obtain a high reward under a variety of potential actions. The temperature
hyperparameter α controls the tradeoff between reward and entropy. In our work, we set this
using automatic temperature tuning (Haarnoja et al., 2018b). Equation 3 is optimized by
minimizing the KL divergence between the action distribution and the distribution induced
by the state-action values:
Jpi(φ) = Est∼D
[
DKL
(
piφ (·|st) ‖exp (Qθ (st, ·))
Zθ (st)
)]
(4)
where D is a replay buffer containing previously seen (st,at, rt, st+1) tuples, Zθ is a
partition function, and Qθ is the state-action value function parameterized by a neural
network (also called a critic). This means that our learned policy engages in probability
matching, selecting an action with probability proportional to its expected value. This
requires an accurate value function. To achieve this, Qθ is trained by minimizing the
temporal difference loss:
JQ(θ) = E(st,at)∼D
[
1
2
(
Qθ (st,at)− Qˆ (st,at)
)2]
, (5)
Qˆ (st,at) = r (st,at) + γEst+1∼p
[
Vψ (st+1)
]
. (6)
Vψ is the soft value function parameterized by a third neural network, and Vψ is the running
exponential average of the weights of Vψ over training. This is a continuous variant of the
hard target network replication in (Mnih et al., 2015). Vψ is trained to minimize:
JV (ψ) = Est∼D
[
1
2
(
Vψ (st)− Eat∼piρ [Qθ (st,at)− log piφ (at|st)]
)2]
. (7)
In summary: we learn a policy that maps from states to a probability distribution
over actions, the policy is parameterized by a neural network piφ. Optimizing this network
(Equation 4) requires an estimation of the soft state-action value function, we learn such an
estimate Qθ (Equation 5) together with a soft value function Vψ (Equation 7). Additional
details of this approach, including the gradient calculations, are given in (Haarnoja et al.,
2018a). In keeping with previous work, when testing our policy we remove the sampling
component, instead selecting the mean action tanh(µ). We replace the MSE temporal
difference loss in Equation 5 with the Huber loss, as we found this improved convergence.
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3.2.1. Recurrent Architecture
Our network piφ takes as input the past 4 hours of CGM and insulin data, requiring no human
input (i.e., no meal announcements). To approximate the true state s∗t from the augmented
state s we parameterize Qθ, Vψ, and piφ using gated-recurrent unit (GRU) networks (Cho
et al., 2014), as GRUs have been successfully used for glucose modeling previously (Fox
et al., 2018; Zhu et al., 2018).
3.2.2. Patient-Specific Action Space
After the network output layer, actions are squashed using a tanh function. Note that this
results in half the action space corresponding to negative values, which we interpret as
administering no insulin. This encourages sparse insulin utilization and makes it easier for
the network to learn to safely control baseline glucose levels. To ensure that the maximum
amount of insulin delivered over a 5-minute interval is roughly equal to a normal meal bolus
for each individual, we use the average ratio of basal to bolus insulin in a day (Kuroda et al.,
2011) to calculate a scale parameter for the action space, ωb = 43.2 ∗ bas, where bas is the
default patient-specific basal insulin rate provided by Xie (2018).
3.3. Efficient Policy Transfer
One of the main disadvantages of deep RL is sample efficiency. Thus, we explored transfer
learning techniques to efficiently transfer existing models to new patients. We refer to
our method trained from scratch as RL-Scratch, and the transfer approach as RL-Trans.
For RL-Trans, we initialize Qθ, Vψ and piφ for each class of patients (children, adolescents,
and adults) using fully trained networks from one patient of that source population (see
Appendix A.4). We then fine-tune these networks on data collected from the target
patient.
When fine-tuning, we modify the reward function by removing the termination penalty
and adding a constant positive value (100) to all rewards. This avoids the negative reward
issue discussed in Section 3.1. Removing the termination penalty increased the consistency
of returns over training, allowing for a more consistent policy gradient. The additional safety
provided by a termination penalty is not required as we begin with policies that are already
stable. We found this simple approach for training patient-specific policies attains good
performance while using far less patient-specific data.
3.4. Baselines
We examine three baseline methods for control: basal-bolus (BB), PID control, and
PID with meal announcements (PID-MA). BB reflects an idealized human-in-the-loop
control strategy, and PID reflects a common closed-loop AP algorithm. PID with meal
announcements is based on current AP technology, and is a combination of the two, requiring
regular human intervention. Finally, we consider an ’oracle’ approach that has access to the
true state s∗t . This decouples the task of learning a policy from state inference, serving as a
pseudo-upper bound on performance for our proposed approach.
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3.4.1. Basal-Bolus Baseline
This baseline is designed to mimic human control and is an ideal depiction of how an
individual with T1D controls their blood glucose. In this setting, we modify the state
representation st to include a carbohydrate signal and a cooldown signal (explained below),
and to remove the historical data, st = [bt, it, ct, cooldown]. Note that the inclusion of a
carbohydrate signal, or meal announcement, places the burden of providing accurate and
timely estimates of meals on the person with diabetes. Each virtual patient in the simulator
comes with the parameters necessary to calculate a reasonable basal insulin rate bas (the
same value used in our action space definition), correction factor CF , and carbohydrate
ratio CR. These three parameters, together with a glucose target bg, define a clinician-
recommended policy pi(st) = bas+ (ct > 0) ∗ ( ctCR + cooldown ∗ bt−bgCF ) where cooldown is 1
if there have been no meals in the past three hours, otherwise it is 0. The cooldown ensures
that each meal is only corrected for once. Appropriate settings for these parameters can
be estimated by endocrinologists, using previous glucose and insulin information (Walsh
et al., 2011). The parameters for our virtual patient population, which are derived from
a distribution validated by clinical trials (Kovatchev et al., 2009), are given in Appendix
A.2.
3.4.2. PID Baseline
PID controllers are a common and robust closed-loop baseline (Steil, 2013). A PID controller
operates by setting the control variable, at, to the weighted combination of three terms
at = kPP (bt)+kII(bt)+kDD(bt) such that the process variable bt (t is the time index) remains
close to a specified setpoint bg. The terms are calculated as follows: i) the proportional term
P (bt) = max(0, bt − bg) increases the control variable proportionally to the distance from
the setpoint, ii) the integral term I(bt) =
∑t
j=0(bj − bg) corrects long-term deviations from
the setpoint, and iii) the derivative term D(bt) = |bt − bt−1| uses the rate of change as a
basic estimate of the future. The set point and the weights (also called gains) kP , kI , kD
are hyperparameters. To compare against the strongest PID controller possible, we tuned
these hyperparameters using multiple iterations of grid-search with exponential refinement
per-patient, minimizing risk. Our final settings are presented in Appendix A.3.
3.4.3. PID with Meal Announcements.
This baseline, which is similar to available hybrid closed loop AP systems (Garg et al., 2017;
Ruiz et al., 2012), combines BB and PID into a control algorithm we call PID-MA. During
meals, insulin boluses are calculated and applied as in the BB approach. The basal rate,
instead of being fixed, is controlled by a PID algorithm, allowing for adaptation between
meals. As above, we tune the gain parameters for the PID algorithm using sequential grid
search to minimize risk.
3.4.4. Oracle Architecture
A deep RL approach to learning AP algorithms requires that the representation learned
by the network contain sufficient information to control the system. As we are working
with a simulator, we can explore the difficulty of this task in isolation, by replacing the
9
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observed state st with the ground-truth state s
∗
t . Though unavailable in real-world settings,
this representation decouples the problem of learning a policy from that of inferring the
state. Here, Qθ, Vψ, and piφ are fully connected with two hidden layers, each with 256 units.
The network uses ReLU nonlinearities and BatchNorm (Ioffe and Szegedy, 2015).
3.5. Experimental Setup & Evaluation
To measure the utility of deep RL for the task of blood glucose control, we trained and tested
our policies on data with different random seeds across 30 different simulated individuals.
Training and Hyperparameters. We trained our models separately for each patient.
They were trained from scratch for 300 epochs for RL-Scratch, and fine-tuned for 50 epochs
for RL-Trans. They were trained with batch size 256 and an epoch length of 20 days. We
used an experience replay buffer of size 1e6 and a discount factor of 0.99. We found that
extensive training from-scratch was required to obtain consistent performance across test
runs. We also found that too small of an epoch length could lead to dangerous control
policies. We optimized the parameters of Qθ, Vψ and piφ using Adam with a learning rate of
3E− 4. All deep networks were composed of two layers of GRU cells with a hidden state size
of 128, followed by a fully-connected output layer. All network hyperparameters, including
number and size of layers, were optimized on training seeds on a subset of the simulated
patients for computational efficiency. Our networks were initialized using PyTorch defaults.
Evaluation. We measured the performance of piφ on 10 days of validation data after each
training epoch. After training, we evaluated on test data using the model parameters from
the best epoch as determined by the validation data. While this form of model selection is
not typical for RL, we found it led to significant changes in performance (see Section 4.2.2).
Our model selection procedure first filters out runs that could not control blood glucose
within safe levels over the validation run (glucose between 30-1000 mg/dL), then selects the
epoch that achieved the lowest risk. We tested each patient-specific model on 1000 days
of test data, broken into 100 independent 10 day rollouts. We trained and evaluated each
approach 3 times, resulting in 3000 days of evaluation per method per person.
We evaluated approaches using i) risk, the average Magni risk calculated over the 10-day
test rollout, ii) % time spent euglycemic (blood glucose levels between 70-180 mg/dL), iii)
% time hypo/hyperglycemic (blood glucose lower than 70 mg/dL or higher than 180 mg/dL
respectively), and iv) % of rollouts that resulted in a catastrophic failure, which we define as
a run that achieves a minimal blood glucose level below 5 mg/dL (at which point recovery
becomes highly unlikely). Note that while catastrophic failures are a major concern, our
simulation process does not consider consuming carbohydrates in reaction to low blood
glucose levels. This is a common strategy to avoid dangerous hypoglycemia in real life, and
thus catastrophic failures, while serious, are manageable. The random seeds controlling
noise, meals, and all other forms of randomness, were different between training, validation,
and test runs. We test the statistical significance of differences between methods using
Mood’s median test for all metrics except for catastrophic failure rate, for which we use a
binomial test.
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4. Experiments and Results
Our experiments are divided into two broad categories: i) experiments showing the benefits
of deep RL for blood glucose control relative to baseline approaches and ii) the challenges of
using deep RL in this setting, and how to overcome them.
Throughout our experiments, we consider 3 variants of RL methods: i) RL-Scratch,
our approach trained from scratch on every individual, ii) RL-Trans, which fine-tunes an
RL-Scratch model from an arbitrary child/adolescent/adult, and iii) RL-MA, which uses
RL-Scratch trained using the automated meal boluses from BB or PID-MA. We also report
results on an Oracle approach, which is trained and evaluated using the ground truth
simulator state.
Figure 2: The risk over 10 days for different simulated patients using methods that do not
require meal announcements. Each point corresponds to a different random test seed that
controls the meal schedule and sensor noise, and the line indicates the median performance
for each method on each patient. Results are presented across 3 random training seeds,
controlling model initialization and randomness in training. We observe that, although there
is a wide range in performance across and within individuals, The RL approaches tend to
outperform PID.
4.1. Advantages of Deep RL
We compare our deep RL approaches to baselines with and without meal announcements
across several metrics (Section 4.1.1). We then investigate two hypotheses for why deep
RL is well suited to the problem of glucose management without meal announcements:
• the high-capacity neural network, integral to the RL approaches, is able to quickly
infer when meals occur (Section 4.1.2), and
11
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Figure 3: The risk over 10 days using methods that require meal announcements. PID-MA
tends to outperform BB, and RL-MA outperforms PID-MA.
• the learning-based approach is able to adapt to predictable meal schedules better than
a PID controller (Section 4.1.3).
4.1.1. Deep RL vs. Baseline Approaches
A comparison between the PID baseline to the RL approaches is presented in Figure 2.
Each point represents a different test rollout by a policy. For the RL approaches, the
performance of each method is reported as the combination of 3 random training restarts.
Among the 3 methods that do not require meal announcements, RL-Scratch performs best
across patients (average rank 1.33), followed by RL-Trans (average rank 1.7), then PID
(average rank 2.97). For each individual, we rank the 3 approaches in terms of median
risk. We calculate average rank by taking the mean of each approach’s rankings across all
30 individuals. Note that RL-Scratch, while achieving strong performance overall, reliably
performs poorly on adolescent#002. We discuss this issue in Appendix A.5.
One major advantage of our proposed approach is its ability to achieve strong perfor-
mance without meal announcements. This does not mean that it does not benefit from
meal announcements, as shown in Figure 3. Among the 3 methods that require meal
announcements, RL-MA performs best (average rank 1.07), followed by PID-MA (average
rank 2.13) then BB (average rank 2.8).
We examine additional metrics in the results presented in Table 1. The difference
between results that are bold, or bold and underlined, and the next best non-bold result
(excluding RL-Oracle) are statistically significant with p < 0.001. We observe that RL-MA
equals or surpasses the performance of all non-oracle methods on all metrics, except for %
time spent hyperglycemia. Interestingly, all RL variants achieve lower median risk than
PID-MA, which requires meal announcements. This is because the RL approaches achieve
12
Deep RL for Blood Glucose Control
low levels of hypoglycemia, which the risk metric heavily penalizes (see Figure 1). Note that
all methods, including PID-MA, were optimized to minimize this metric. Across patients,
the RL methods achieve approximately 60-80% time euglycemic, compared with 52%±19.6%
observed in real human control (Ayano-Takahara et al., 2015). These results suggest that
deep RL could be a valuable tool for closed-loop or hybrid closed-loop AP control.
Table 1: Median risk, percent of time Eu/Hypo/Hyperglycemic, and failure rate calculated
using 1000 days of simulation broken into 100 independent 10-day rollouts for each of 3
training seeds for 30 patients, totaling 90k days of evaluation (with interquartile range).
Lower Magni Risk, Hypoglycemia, and Hyperglycemia are better, higher Euglycemia is better.
Hybrid and Non-closed loop approaches (requiring meal announcements) are indicated with
*. Approaches requiring a fully observed simulator state are indicated with †. The non-oracle
approach with the best average score is in bold and underlined, the best approach that does
not require meal announcements is in bold.
Risk Euglycemia Hypoglycemia Hyperglycemia Failure
↓ (%) ↑ (%) ↓ (%) ↓ (%) ↓
N
o
M
A PID 8.86 (6.8-14.3) 71.68 (65.9-75.9) 1.98 (0.3-5.5) 24.71 (21.1-28.6) 0.12
RL-Scratch 6.50 (4.8-9.3) 72.68 (67.7-76.2) 0.73 (0.0-1.8) 26.17 (23.1-30.6) 0.07
RL-Trans 6.83 (5.1-9.7) 71.91 (66.6-76.2) 1.04 (0.0-2.5) 26.60 (22.7-31.0) 0.22
M
A
BB∗ 8.34 (5.3-12.5) 71.09 (62.2-77.9) 2.60 (0.0-7.2) 23.85 (17.0-32.2) 0.26
PID-MA∗ 8.31 (4.7-10.4) 76.54 (70.5-82.0) 3.23 (0.0-8.8) 18.74 (12.9-23.2) 0.00
RL-MA∗ 4.24 (3.0-6.5) 77.12 (71.8-83.0) 0.00 (0.0-0.9) 22.36 (16.6-27.7) 0.00
RL-Oracle† 3.58 (1.9-5.4) 78.78 (73.9-84.9) 0.00 (0.0-0.0) 21.22 (15.1-26.1) 0.01
4.1.2. Detecting Latent Meals
Our approach achieves strong blood glucose control without meal announcements, but how
much of this is due to the ability to react to meals? To investigate this, we looked at the
total proportion of insulin delivered on average after meals for PID and RL-Scratch, shown
in Figure 4a. A method able to infer meals should use insulin rapidly after meals, as the
sooner insulin is administered the faster glycemic spikes can be controlled while avoiding
hypoglycemia. We observe that RL-Scratch administers the majority of its post-meal bolus
within one hour of a meal, whereas PID requires over 90 minutes, suggesting RL-Scratch
can indeed better infer meals. Interestingly, when considering the percentage of total daily
insulin administered in the hour after meals, RL-Scratch responds even more aggressively
than BB or PID-MA (54.7% vs. 48.5% and 47.3% respectively). This demonstrates that our
RL approach is able to readily react to latent meals shortly after they have occurred.
4.1.3. Ability to Adapt to Predictable Meal Schedules
We hypothesize that one advantage of RL is its ability to compensate for predictable
variations (such as meals) in the environment, improving control as the environment becomes
more predictable. To test this benefit, we changed the meal schedule generation procedure
outlined in Algorithm 1 (Appendix A.1) for Adult 1. We removed the small ‘snack’
meals, set all meal occurrence probabilities to 1, and made meal amounts constant (i.e., each
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Figure 4: a) The average amount of insulin (in percent of total daily insulin) provided after
meals for PID and RL-Scratch (note: RL-Trans, unshown, is very similar to RL-Scratch).
RL-Scratch is able respond to meals more quickly than PID, with insulin peaking 30 minutes
post-meal as opposed to roughly 60 minutes for PID. Additionally, the RL approach finishes
delivering most post-meal insulin after 1hr, PID takes over 90 minutes. b) The distribution
of average risk scores over 300 10-day rollouts for Adult 1 using meal schedules with varying
amounts of predictability (meal time standard deviation). While PID performs better with
more regularly spaced meals (median risk lowers from 9.66 at std=10 to 8.53 at std=0.1, a
12% decrease), RL-Scratch sees a larger proportional and absolute improvement (median
risk lowers from 8.33 at std=10 to 6.36 at std=0.1, a 24% decrease).
day Adult 1 consumes an identical set of meals). We then evaluated both the PID model
and RL-Scratch on 3 variations of this environment, characterized by the standard deviation
of the meal times (either 0.1, 1, or 10 hours). This tests the ability of each method to take
advantage of patterns in the environment. As the standard deviation decreases, the task
becomes easier for two reasons: i) there are fewer instances where two meals occur in quick
succession, and ii) the meals become more predictable. The results are presented in Figure
4b. We observe that both methods improve in performance as the standard deviation
decreases, likely due to (i). However, while RL-Scratch outperforms PID under all settings,
the difference increases as the standard deviation of meal times decreases, suggesting RL
is better able to leverage the predictability of meals. Specifically, mean risk decreases by
roughly 12% for the PID approach (from 9.65 to 8.54), whereas it decreases nearly 24% for
the RL approach (from 8.40 to 6.42). This supports our hypothesis that RL is better able
to take advantage of predictable meal schedules.
4.2. Challenges for Deep RL
While in the previous section we demonstrated several advantages of using deep RL for
blood glucose control, here we emphasize that the application of deep RL to this task and
its evaluation are non-trivial. Specifically, in this section we:
• demonstrate the importance of our action space formulation for performance (Section
4.2.1),
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• illustrate the critical need for careful and extensive validation, both for model selection
and evaluation (Section 4.2.2).
• show that, applied naively, deep RL leads to an unacceptable catastrophic failure rate,
and present three simple approaches to improve this (Section 4.2.3),
• address the issue of sample complexity with simple policy transfer (Section 4.2.4).
4.2.1. Developing an Effective Action Space
One challenging element of blood glucose control in an RL setting is defining the action
space. Insulin requirements vary significantly by person (from 16 to 60 daily units in the
simulator population we use), and throughout most of the day, insulin requirements are
much lower than after meals. To account for these challenges, we used a patient-specific
action space, where much of the space corresponds to delivering no insulin (discussed in
Section 3.2.1). We perform an ablation study to test the impact of these decisions. On an
arbitrarily chosen patient (child#001), we shifted the tanh output to remove the negative
insulin space. This increased the catastrophic failure rate from 0% (on this patient) to 6.6%.
On a challenging subset of 4 patients (indicated in Appendix A.2), we looked at the effect
of removing the patient-specific action scaling ωb. This resulted in a 13% increase in median
risk from 9.92 to 11.23. These results demonstrate that a patient-specific action space that
encourages conservative behavior can improve performance.
4.2.2. Potential Pitfalls in Evaluation
In our experiments, we observed two key points for model evaluation: i) while often overlooked
in RL, using validation data for model selection during training was key to achieving good
performance, and ii) without evaluating on far more data than is typical, it was easy to
underestimate the catastrophic failure rate.
Performance instability necessitates careful model selection. Off-policy RL with
function approximation, particularly deep neural networks, is known to be unstable (Sutton
and Barto, 2018; Gottesman et al., 2018). As a result, we found it was extremely important
to be careful in selecting which network (and therefore policy) to evaluate. In Figure 5a,
we show the fluctuation in validation performance over training for Adult#009. While
performance increases on average over the course of training (at least initially), there are
several points where performance degrades considerably. Figure 5b shows how performance
averaged over all patients changes depending on the approach used to select the policy for
evaluation. When we simply evaluate using the final epoch, almost half of test rollouts end
in a catastrophic failure. Surprisingly, even when we select the model that minimized risk on
the validation set, nearly a fifth of rollouts fail. However, by first limiting our pool of models
to those that achieve a minimum blood glucose level of at least 30 mg/dL over the validation
data, we reduce the catastrophic failure rate to 0.07%. As performance instability has been
noted in other RL domains (Islam et al., 2017; Henderson et al., 2018), this observation is
likely relevant to other applications of deep RL in healthcare.
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Figure 5: a) The training and validation curve (average reward) for adult#009. Note the
periods of instability affect both training and validation performance. b) Catastrophic failure
rate over all patients for 3 methods of model selection: i) selecting the final training epoch,
ii) selecting the epoch that achieved minimal risk, and iii) selecting the minimal risk epoch
that maintained blood glucose above 30 mg/dL. We see large differences in performance
depending on the model selection strategy.
Extensive evaluation is necessary. Health applications are often safety critical. Thus,
the susceptibility of deep RL to unexpected or unsafe behavior can pose a significant risk
(Leike et al., 2017; Futoma et al., 2020). While ongoing work seeks to provide safety
guarantees in control applications using deep learning (Achiam et al., 2017; Futoma et al.,
2020), it is important that practitioners take every step to evaluate the safety of their
approaches. While it is typical to evaluate RL algorithms on a small number of rollouts
(Henderson et al., 2018), in our work we saw how easy it can be to miss unsafe behavior,
even with significant testing. We examined the number of catastrophic failures that occurred
using RL-Trans using different evaluation sets. Over our full evaluation set of 9,000 10-day
rollouts, we observed 20 catastrophic failures (a rate of 0.22%). However, when we only
evaluated using the first 5 test seeds, which is still over 12 years of data, we observed 0
catastrophic failures. Additionally, when we evaluated using 3-day test rollouts instead of 10,
we only observed only 5 catastrophic failures (a rate of .05%), suggesting that longer rollouts
result in a higher catastrophic failure rate. These results demonstrate that, particularly
when dealing with noisy observations, it is critical to evaluate potential policies using a large
number of different, lengthy rollouts.
4.2.3. Reducing Catastrophic Failures
Due to their potential danger, avoiding catastrophic failures was a significant goal of this
work. The most direct approach we used was to modify the reward function, using a large
termination penalty to discourage dangerous behavior. While unnecessary for fine-tuning
policies, when training from scratch this technique was crucial. On a subset of 6 patients
(see Appendix A.4), including the termination penalty reduced the catastrophic failure
rate from 4.2% to 0.2%.
We found varying the training data also had a major impact on the catastrophic failure
rate. During training, every time we reset the environment we used a different random seed
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Table 2: Risk and percent of time Eu/Hypo/Hyperglycemic calculated for the RL approaches
treating the 3 training seeds as different random restarts. The stability of the Scratch and
Trans approaches improves relative to performance in Table 1.
Risk Euglycemia Hypoglycemia Hyperglycemia Failure Rate
↓ (%) ↑ (%) ↓ (%) ↓ (%) ↓
RL-Scratch 6.39 (4.7-8.9) 72.96 (69.1-76.6) 0.62 (0.0-1.7) 25.96 (22.7-29.6) 0.00
RL-Trans 6.57 (5.0-9.3) 71.56 (67.0-75.7) 0.80 (0.0-1.9) 27.19 (23.4-31.2) 0.13
RL-MA 3.71 (2.7-6.3) 77.36 (72.7-83.2) 0.00 (0.0-0.5) 22.45 (16.7-26.9) 0.00
(which controls meal schedule and sensor noise). Note that the pool of training, validation,
and test seeds were non-overlapping. On a challenging subset of 7 patients (described in
Appendix A.4), we ran RL-Scratch with and without this strategy. The run that varied
the training seeds had a catastrophic failure rate of 0.15%, the run that didn’t had a 2.05%
rate (largely driven by adult#009, who reliably had the highest catastrophic failure rate
across experiments).
Other approaches can further improve stability. In Table 1, our RL results are averaged
over three random restarts in training. This was done to demonstrate that our learning
framework is robust to randomness in training data and model initialization. However, in
a real application it would make more sense to select (using validation data) one model
for use out of the random restarts. We apply this approach in Table 2, choosing the seed
that obtained the best performance according to our model selection criteria. This improves
all the RL methods. Most notably, it further reduces the catastrophic failure rate for the
approaches without meal announcements (0.07% to 0% for RL-Scratch, and 0.22% to 0.13%
for RL-Trans).
4.2.4. Sample Efficiency and Policy Transfer
While RL-Scratch achieves strong performance on average, it requires a large amount of
patient-specific data: 16.5 years per patient. While RL-Trans reduced this amount, it still
required over 2 years of patient-specific data, which for most health applications would be
infeasible. Thus, we investigated how performance degrades as less data is used.
In Figure 6, we show the average policy performance by epoch for both RL-Scratch and
RL-Trans relative to the PID controller. Note the epoch determines the maximum possible
epoch for our model selection, not the actual chosen epoch. We see that far less training is
required to achieve good performance with RL-Trans. In over 40% of rollouts, RL-Trans
outperforms PID with no patient-specific data (median risk 10.31), and with 10 epochs of
training (roughly half a year of data) RL-Trans outperforms PID in the majority of rollouts
(59.6%; median risk 7.95).
Interestingly, the lack of patient-specific data does not appear to cause excessive catas-
trophic failures. With no patient-specific data the failure rate is 0%, after 5 epochs of
training it has risen to .5%, and then declines over training to the final value of .22%.
This implies two things: i) patient-specific training can increase the catastrophic failure
rate, possibly by learning overly aggressive treatment policies, and ii) our current model
selection procedure does not minimize the catastrophic failure rate. We do not observe this
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Figure 6: The proportion of test rollouts where RL-Scratch and RL-Trans outperform the
median PID risk with different amounts of patient-specific training. We see that without
any patient-specific data RL-Trans performs better than PID in 40% of rollouts. RL-
Scratch requires a significant amount of patient-specific data before achieving comparable
performance.
for RL-Scratch, where all epochs under 50 achieve a catastrophic error rate of over 17%.
These results suggest that our simple transfer approach can be effective even with limited
amounts of patient-specific data.
5. Conclusion
In this work, we demonstrated how deep RL can lead to significant improvements over
alternative approaches to blood glucose control, with and without meal announcements
(Section 4.1.1). We provide insight into why (Section 4.1.2) and when (Section 4.1.3)
we would expect to see RL perform better. We demonstrated the importance of a robust
action space in patient-specific tasks (Section 4.2.1), showed how careful and extensive
validation is necessary for realistic evaluation of performance(Section 4.2.2), investigated
several simple and general approaches to improving the stability of deep RL (Section
4.2.3), and developed a simple approach to reduce the requirements of patient-specific data
(Section 4.2.4). While the main goal of this paper was to advance a clinical application,
the challenges we encountered and the solutions they inspired are likely to be of interest to
researchers applying RL to healthcare more broadly.
While our results in applying deep RL to blood glucose control are encouraging, they come
with several limitations. First, our results are based on simulation. The simulator may not
adequately capture variation across patients or changes in the glucoregulatory system over
time. In particular, the virtual patient population the simulator comes equipped with does
not differentiate individuals based on demographic information, such as gender and ethnicity.
Thus, the applicability of our proposed techniques to all relevant patient populations cannot
be assessed. However, as an FDA-approved substitute for animal trials (Kovatchev et al.,
2009), success in using this simulator is a nontrivial accomplishment. Second, we define a
reward function based on risk. Though optimizing this risk function should lead to tight
glucose control, it could lead to excess insulin utilization (as its use is unpenalized). Future
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work could consider resource-aware variants of this reward. Third, our choice of a 4-hour
state space discourages learning long-term patterns or trends. In our environment, this did
not reduce performance relative to a longer input history, but this could be important for
managing blood glucose levels in more realistic simulators or real-world cases Visentin et al.
(2018). Finally, we emphasize that blood glucose control is a safety-critical application. An
incorrect dose of insulin could lead to life-threatening situations. Many of the methods we
examined, even those that achieve good average performance, are susceptible to catastrophic
failures. We have investigated several ways to minimize such failures, including modifying
the reward function and selecting models across multiple random restarts. While the results
from Table 2 suggest these approaches mitigate catastrophic failures, the results of Section
4.2.2 show such empirical evaluations can miss failure cases. To enable researchers to better
explore and correct these limitations, we evaluated on an open-source simulator and made
all the code required to reproduce our experiments publicly available.
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Appendix A. Appendix
A.1. Harrison-Benedict Meal Generation Algorithm
See Algorithm 1. In short, this meal schedule calculates BMR for each simulated individual
using the Harrison-Benedict equation (Harris and Benedict, 1919). This is used to estimate
expected daily carbohydrate consumption, assuming individuals eat a reasonably low-carb
diet where 45% of calories come from carbohydrates. Daily carbohydrates were divided
between 6 potential meals: breakfast, lunch, dinner, and 3 snacks. The occurrence probability
of the meal and expected size of the meal was set such that the expected number of carbs eaten
per day matched the BMR-derived estimate. Note, in our experiments our implementation
of of this meal schedule incorrectly estimated ages for many patients, particularly adults.
This effect was fairly minor, resulting in no more than a 10% change in estimated BMR.
Algorithm 1 Generate Meal Schedule
Input: body weight w, age a, height h, number of days n
BMR = 66.5 + (13.75 ∗ w) + (5.003 ∗ h)− (6.755 ∗ a)
ExpectedCarbs = (BMR ∗ 0.45)/4 {45% of calories assumed from carbs, 4 calories per
carb}
MealOcc = [0.95, 0.3, 0.95, 0.3, 0.95, 0.3]
TimeLowerBounds = [5, 9, 10, 14, 16, 20] ∗ 12
TimeUpperBounds = [9, 10, 14, 16, 20, 23] ∗ 12
TimeMean = [7, 9.5, 12, 15, 18, 21.5] ∗ 12
TimeStd = [1, .5, 1, .5, 1, .5] ∗ 12
AmountMean = [0.250, 0.035, 0.295, 0.035, 0.352, 0.035] ∗ ExpectedCarbs ∗ 1.2
AmountStd = AmountMean ∗ 0.15
Days = []
for i ∈ [1, . . . , n] do
M = [0]288j=1
for j ∈ [1, . . . , 6] do
m ∼ Binomial(MealOcc[j])
lb = TimeLowerBounds[j]
ub = TimeUpperBounds[j]
µt = TimeMean[j]
σt = TimeStd[j]
µa = AmountMean[j]
σa = AmountStd[j]
if m then
t ∼ Round(TruncNormal(µt, σt, lb, ub))
c ∼ Round(max(0, Normal(µa, σa)))
M [t] = c
end if
end for
Days.append(M)
end for
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Person CR CF Age TDI
child#001 28.62 103.02 9 17.47
child#002 27.51 99.02 9 18.18
child#003 31.21 112.35 8 16.02
child#004 25.23 90.84 12 19.82
child#005 12.21 43.97 10 40.93
child#006 24.72 89.00 8 20.22
child#007 13.81 49.71 9 36.21
child#008 23.26 83.74 10 21.49
child#009 28.75 103.48 7 17.39
child#010 24.21 87.16 12 20.65
adolescent#001 13.61 49.00 18 36.73
adolescent#002 8.06 29.02 19 62.03
adolescent#003 20.62 74.25 15 24.24
adolescent#004 14.18 51.06 17 35.25
adolescent#005 14.70 52.93 16 34.00
adolescent#006 10.08 36.30 14 49.58
adolescent#007 11.46 41.25 16 43.64
adolescent#008 7.89 28.40 14 63.39
adolescent#009 20.77 74.76 19 24.08
adolescent#010 15.07 54.26 17 33.17
adult#001 9.92 35.70 61 50.42
adult#002 8.64 31.10 65 57.87
adult#003 8.86 31.90 27 56.43
adult#004 14.79 53.24 66 33.81
adult#005 7.32 26.35 52 68.32
adult#006 8.14 29.32 26 61.39
adult#007 11.90 42.85 35 42.01
adult#008 11.69 42.08 48 42.78
adult#009 7.44 26.78 68 67.21
adult#010 7.76 27.93 68 64.45
Table 3: Basal-Bolus Parameters
A.2. BB Parameters
The parameters are presented in Table 3. The simulator provides age and TDI for each
individual. To calculate CR and CF we use equations CR = 500/TDI and CF = 1800/TDI,
which were provided to us via a clinical consultation. The resulting CR and CF we used
differed from those provided in the baseline Simglucose download from Xie (2018), in practice
we found our values led to better performance.
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A.3. PID and PID-MA parameters
kp ki kd
child#001 -3.49E-05 -1.00E-07 -1.00E-03
child#002 -3.98E-05 -2.87E-08 -3.98E-03
child#003 -6.31E-05 -1.74E-08 -1.00E-03
child#004 -6.31E-05 -1.00E-07 -1.00E-03
child#005 -1.00E-04 -2.87E-08 -6.31E-03
child#006 -3.49E-05 -1.00E-07 -1.00E-03
child#007 -3.98E-05 -6.07E-08 -2.51E-03
child#008 -3.49E-05 -3.68E-08 -1.00E-03
child#009 -3.49E-05 -1.00E-07 -1.00E-03
child#010 -4.54E-06 -3.68E-08 -2.51E-03
adolescent#001 -1.74E-04 -1.00E-07 -1.00E-02
adolescent#002 -1.00E-04 -1.00E-07 -6.31E-03
adolescent#003 -1.00E-04 -1.00E-07 -3.98E-03
adolescent#004 -1.00E-04 -1.00E-07 -4.79E-03
adolescent#005 -6.31E-05 -1.00E-07 -6.31E-03
adolescent#006 -4.54E-10 -1.58E-11 -1.00E-02
adolescent#007 -1.07E-07 -6.07E-08 -6.31E-03
adolescent#008 -4.54E-10 -4.54E-12 -1.00E-02
adolescent#009 -6.31E-05 -1.00E-07 -3.98E-03
adolescent#010 -4.54E-10 -4.54E-12 -1.00E-02
adult#001 -1.58E-04 -1.00E-07 -1.00E-02
adult#002 -3.98E-04 -1.00E-07 -1.00E-02
adult#003 -4.54E-10 -1.00E-07 -1.00E-02
adult#004 -1.00E-04 -1.00E-07 -3.98E-03
adult#005 -3.02E-04 -1.00E-07 -1.00E-02
adult#006 -2.51E-04 -2.51E-07 -1.00E-02
adult#007 -1.22E-04 -3.49E-07 -2.87E-03
adult#008 -1.00E-04 -1.00E-07 -1.00E-02
adult#009 -1.00E-04 -1.00E-07 -1.00E-02
adult#010 -1.00E-04 -1.00E-07 -1.00E-02
Table 4: PID parameters
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kp ki kd
child#001 -5.53E-09 -1.00E-07 -3.49E-04
child#002 -1.00E-04 -2.87E-08 -1.00E-03
child#003 -1.00E-05 -2.87E-08 -1.00E-03
child#004 -6.31E-05 -1.00E-07 -1.00E-03
child#005 -1.00E-04 -1.00E-07 -3.31E-03
child#006 -1.00E-05 -3.68E-08 -1.00E-03
child#007 -2.35E-07 -1.00E-07 -1.00E-03
child#008 -4.72E-06 -2.87E-08 -1.00E-03
child#009 -1.00E-05 -1.00E-07 -3.49E-04
child#010 -3.49E-05 -4.72E-08 -1.00E-03
adolescent#001 -1.00E-04 -4.72E-08 -6.31E-03
adolescent#002 -1.00E-05 -1.00E-07 -3.49E-03
adolescent#003 -6.31E-05 -1.00E-07 -2.09E-03
adolescent#004 -6.31E-05 -1.00E-07 -2.51E-03
adolescent#005 -4.79E-05 -1.00E-07 -3.98E-03
adolescent#006 -1.00E-04 -1.00E-07 -2.75E-03
adolescent#007 -1.00E-05 -1.00E-07 -3.02E-03
adolescent#008 -1.58E-09 -1.00E-07 -2.75E-03
adolescent#009 -3.98E-05 -1.00E-07 -1.91E-03
adolescent#010 -1.00E-04 -1.00E-07 -4.37E-03
adult#001 -1.07E-07 -1.00E-07 -4.37E-03
adult#002 -1.58E-04 -1.00E-07 -4.37E-03
adult#003 -7.59E-05 -1.00E-07 -2.51E-03
adult#004 -1.00E-04 -1.00E-07 -1.00E-03
adult#005 -1.07E-07 -1.00E-07 -6.31E-03
adult#006 -1.00E-04 -1.00E-07 -1.00E-02
adult#007 -1.58E-04 -2.51E-07 -3.02E-03
adult#008 -1.58E-05 -1.00E-07 -3.98E-03
adult#009 -4.54E-10 -1.00E-07 -6.31E-03
adult#010 -3.98E-05 -1.00E-07 -4.37E-03
Table 5: PID-MA parameters
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A.4. Relevant Patient Subgroups
For tuning our models and selecting hyperparameters, we focused on one challenging but rep-
resentative individual from each category. In particular, we used child#001, adolescent#004,
and adult#001.
For our action space ablation, we examined the subset of 4 individuals who were most
prone to catastrophic failures: child#006, child#008, adolescent#002, and adult#009
For the termination penalty experiment, we included child#001, child#003, adoles-
cent#002, adolescent#008, adult#008, and adult#009. We used these patients as they
contained a mix of regular and hard to control patients.
For seed progression experiments, we focused on a subset of patients we found reliably
challenging for different models to control (in terms of risk and catastrophic failure rate).
We included child#001, child#006, child#008, adolescent#002, adolescent#003, adult#001,
and adult#009 in this analysis.
A.5. RL-Scratch on Adolescent#002
RL-Scratch has a distinct form of degenerate behavior that occurs only in adolescent#002,
drastically lowering performance (see Figure 2). We reliably observe that models trained
on adolescent#002 do not administer any insulin, and thus achieve chronic hyperglycemia.
This is because, unlike any other virtual patient, adolescent#002 does not require any insulin
to achieve blood glucose levels below 1000 mg/dL (the threshold at which we apply the
hyperglycemic termination penalty) over a 10-day period. As a result of the large disparity
between average rewards and the termination penalty, the network quickly learns to never
administer insulin and the learned exploration rate collapses to 0. This approach can be
easily avoided by warm-starting using an environment from another individual, as then the
network has already learned to administer generally safe amounts of insulin. Adolescent#002
spends, on average, 97% of their time hyperglycemic under RL-Scratch, and only 39.2% of
time hyperglycemic under RL-Trans.
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